Peptide Library

Human study PLS-00191

Thymosin β4 and β10 in Sjögren's syndrome: saliva proteomics and minor salivary glands expression.

Cross-sectional study · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Thymosin β4 and β10 in Sjögren's syndrome: saliva proteomics and minor salivary glands expression.primary · Arthritis research & therapy · 2016-10-06 · PMID 27716395 · DOI

Design and participants

Design
Cross-sectional study
Population
Patients with primary Sjögren's syndrome; patients with systemic sclerosis, systemic lupus erythematosus or rheumatoid arthritis, with and without sicca syndrome; and healthy subjects.
Conditions
Primary Sjögren's syndrome, Systemic sclerosis, Systemic lupus erythematosus, Rheumatoid arthritis, Sicca syndrome
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported
Funding
Research Support, Non-U.S. Gov't (per publication type); funder not named in record.

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Higher salivary thymosin β4 characterizes primary Sjögren's syndrome, while salivary Tβ4 sulfoxide and Tβ10 appear only in patients with sicca symptoms. In pSS, minor salivary glands show Tβ10 staining without Tβ4, suggesting different roles for the two peptides.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Thymosin β4 was measured as an endogenous biomarker and was not administered, so the study gives no evidence on the effects of treatment.
    • small or imprecise: Each disease subgroup had only seven to ten participants according to the abstract.
    • abstract only: Only the abstract is available in the record, so methods and full results cannot be checked.
    • inappropriate endpoint: Endogenous thymosin levels and immunostaining are biomarkers. No thymosin was administered, so no treatment effect or safety can be judged.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 27716395, abstract (Conclusions, sentences 1-3) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 27716395, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • funding: PMID 27716395, title (publication types metadata) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 27716395, abstract (Background, sentence 1; Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).